Page 11 - Transformative Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Emerging from Stealth Mode, Gene Editing Startup Prime Medicine Raises $315M July 14, 2021 Source: CIPhotos/Getty Images Prime Medicine, whose “search and replace” approach to gene editing underpins the second genome editing technology to be commercialized by the lab of David R. Liu, Ph.D., and colleagues, said today it has completed $315 million in financing, ending nearly a year of operation in stealth mode. The financing consists of a $115 million Series A round and a $200 million series B round. Prime said proceeds from the financing will be used to continue building the company, rap...

First Positive Data of In Vivo CRISPR-Based Genome Editing in Humans Reported June 28, 2021 A team of researchers based in the U.S., the U.K., and New Zealand from Intellia Therapeutics, Regeneron Pharmaceuticals, and clinical partners showed in a study that the companies’ lead in vivo genome editing candidate NTLA-2001 generated a dose-dependent sustained reduction of protein linked to transthyretin (ATTR) amyloidosis following a single dose in six patients living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The study is the first ever to support the safety an...

In collaboration with the Permanent Mission of the Federal Republic of Germany to the United Nations and Global Project Against Hate and Extremism, the World Jewish Congress is organizing a virtual event entitled “Trends in Financing Far-Right Violent Extremism” on 28 June. The event will explore the confluence of the coronavirus pandemic and the financing of far-right violent extremism, in particular discussing the influence of new technologies and online capabilities such as the improper use of cryptocurrency, the selling of hate merchandise and the use of social media f...

A setting sun used to mean that Ruby Kumari had to close the doors to her home-made sewing school in Parsa, a village in the eastern Indian state of Bihar. But the arrival of solar-powered minigrids in 2019 allowed her to stay open after sundown and offer additional classes, more than doubling enrolment to 80. Access to affordable, reliable power also meant she could switch from manual to electric sewing machines, helping her transform her skills into a new business activity in 2020 when the COVID-19 pandemic put her teaching work on hold.

Broad Institute of MIT and Harvard Sickle cell disease (SCD) is the most common deadly genetic disorder, affecting more than 300,000 newborns worldwide each year. It leads to chronic pain, organ failure, and early death in patients. A team led by researchers at the Broad Institute of MIT and Harvard and St. Jude Children’s Research Hospital has now demonstrated a base editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This gene editing treatment rescued the disease symptoms in animal models, enabling the long-lasting production of...